

Benjamin N Rome

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/371431/publications.pdf>

Version: 2024-02-01

43
papers

1,821
citations

623734

14
h-index

289244

40
g-index

43
all docs

43
docs citations

43
times ranked

2302
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis. <i>New England Journal of Medicine</i> , 2013, 368, 1675-1684.	27.0	515
2	The Dramatic Increase in Total Knee Replacement Utilization Rates in the United States Cannot Be Fully Explained by Growth in Population Size and the Obesity Epidemic. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012, 94, 201-207.	3.0	409
3	Lifetime Risk and Age at Diagnosis of Symptomatic Knee Osteoarthritis in the US. <i>Arthritis Care and Research</i> , 2013, 65, 703-711.	3.4	304
4	Drug Evaluation during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 382, 2282-2284.	27.0	133
5	FDA Approval of Cardiac Implantable Electronic Devices via Original and Supplement Premarket Approval Pathways, 1979-2012. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 385.	7.4	58
6	Trends in Prescription Drug Launch Prices, 2008-2021. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2145.	7.4	45
7	Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty. <i>PLoS ONE</i> , 2013, 8, e62709.	2.5	28
8	Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology. <i>Current Cardiology Reports</i> , 2014, 16, 489.	2.9	26
9	Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 367-371.	4.7	26
10	A Comparison of Patient-Reported and Measured Range of Motion in a Cohort of Total Knee Arthroplasty Patients. <i>Journal of Arthroplasty</i> , 2014, 29, 1378-1382.e1.	3.1	25
11	Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. <i>American Heart Journal</i> , 2021, 233, 109-121.	2.7	23
12	Estimating Rebates and Other Discounts Received by Medicare Part D. <i>JAMA Health Forum</i> , 2021, 2, e210626.	2.2	18
13	Use of "Doctor" Badges for Physician Role Identification During Clinical Training. <i>JAMA Internal Medicine</i> , 2019, 179, 1582.	5.1	16
14	Medical Device Innovation "Is" "Better" Good Enough?. <i>New England Journal of Medicine</i> , 2011, 365, 1464-1466.	27.0	15
15	Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs. <i>JAMA Network Open</i> , 2021, 4, e218816.	5.9	15
16	Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation. <i>Milbank Quarterly</i> , 2021, 99, 240-272.	4.4	14
17	Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1671-1675.	5.8	11
18	The Future of Drug-Pricing Transparency. <i>New England Journal of Medicine</i> , 2021, 384, 489-491.	27.0	11

#	ARTICLE	IF	CITATIONS
19	Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?. JAMA Internal Medicine, 2021, 181, 1034.	5.1	11
20	Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary. JAMA Internal Medicine, 2020, 180, 597.	5.1	10
21	Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company. Annals of Internal Medicine, 2022, 175, 1053-1055.	3.9	10
22	Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States. JAMA Internal Medicine, 2021, 181, 995-997.	5.1	8
23	Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. Value in Health, 2021, 24, 804-811.	0.3	8
24	Medicare Spending on Drugs With Accelerated Approval, 2015-2019. JAMA Health Forum, 2021, 2, e213937.	2.2	8
25	Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. Health Affairs, 2017, 36, 362-370.	5.2	7
26	US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate. JAMA Internal Medicine, 2020, 180, 1165.	5.1	7
27	Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals. JAMA Internal Medicine, 2022, 182, 83.	5.1	7
28	Sex-Based Role Misidentification and Burnout of Resident Physicians. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	7
29	Raising Medicaid Rebates For Drugs With Accelerated Approval. Health Affairs, 2021, 40, 1935-1942.	5.2	7
30	Effect of Shared Electronic Health Records on Duplicate Imaging after Hospital Transfer. Journal of General Internal Medicine, 2020, 35, 1617-1619.	2.6	6
31	Drug Prices, Rebates, and Discounts. JAMA - Journal of the American Medical Association, 2020, 324, 399.	7.4	4
32	Federal Spending on Off-Patent Drugs That Lack Generic Competition. Journal of General Internal Medicine, 2021, 36, 821-823.	2.6	4
33	Frequency Of Generic Drug Price Spikes And Impact On Medicaid Spending. Health Affairs, 2021, 40, 779-785.	5.2	4
34	Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative. JAMA Internal Medicine, 2021, 181, 1124.	5.1	4
35	Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020. JAMA Internal Medicine, 2022, 182, 342.	5.1	4
36	Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules. JAMA Network Open, 2021, 4, e2134463.	5.9	3

#	ARTICLE	IF	CITATIONS
37	Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling. <i>Journal of Clinical Oncology</i> , 2022, 40, 1102-1110.	1.6	3
38	Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?. <i>Annals of Internal Medicine</i> , 2022, 175, 890-891.	3.9	3
39	Association of California's Prescription Drug Coupon Ban With Generic Drug Use. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2399.	7.4	2
40	Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. <i>JAMA Network Open</i> , 2021, 4, e2135362.	5.9	1
41	State Laws and Generic Substitution in the Year After New Generic Competition. <i>Value in Health</i> , 2022, , .	0.3	1
42	Reply to Boucher et al. <i>Clinical Infectious Diseases</i> , 2021, 72, e422-e423.	5.8	0
43	Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic. <i>Journal of General Internal Medicine</i> , 2021, 36, 3918-3921.	2.6	0